| Hans-Günter Meyer-Thompson | HIV
WHO recommends dolutegravir as preferred HIV treatment option in all populations
WHO recommends dolutegravir as preferred HIV treatment option in all populations
Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. (WHO, 22.07.2019)